Korro Bio (KRRO) News
NASDAQ: KRROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.18-0.01 (-0.08%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KRRO news summary
We found 4 recent headlines mentioning Korro Bio (KRRO): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, KRRO is down 0.08% at $12.18. The most recent story, "Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Korro Bio headlines
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA…GlobeNewswire
- Korro to Present at the 2026 Jefferies Global Healthcare Conference in LondonCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA…GlobeNewswire
- Korro Bio Announces Preclinical Results for KRRO-111Korro Bio, Inc. announced preclinical results for KRRO-111, its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency. KRRO-111 is a proprietary GalNAc-conjugated…Nasdaq
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA…GlobeNewswire